SCHEDULE: Lilly Endowment Reports 9.7% Stake in Eli Lilly
Beneficial Ownership Filing
Lilly Endowment, Inc. has disclosed a beneficial ownership of 91,896,978 shares, representing 9.7% of Eli Lilly and Company's common stock as of March 31, 2026.
Summary
- Lilly Endowment, Inc. has filed a Schedule 13G, indicating its beneficial ownership of Eli Lilly and Company's common stock.
- As of March 31, 2026, the Endowment holds 91,896,978 shares, which constitutes 9.7% of the outstanding common stock.
- The Endowment possesses sole voting power and sole dispositive power over these shares.
- The percentage of class is based on 944,818,881 shares outstanding as of February 25, 2026, as reported in Eli Lilly's definitive proxy statement for its 2026 annual meeting.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is a standard disclosure of existing ownership and does not contain new financial performance data or strategic changes.
Positives
- Lilly Endowment, Inc. maintains a significant, stable ownership stake in Eli Lilly and Company.
- The Endowment has sole voting and dispositive power, indicating clear control over its investment.
Future Outlook
No specific forward-looking statements or guidance are provided in this Schedule 13G filing, which is a disclosure of current ownership status.
Industry Context
StockSavvy.ai notes that this filing is a routine disclosure for a significant institutional investor like Lilly Endowment, Inc., highlighting its long-standing and substantial investment in Eli Lilly and Company. Such filings are crucial for understanding the major holders of a company's stock and their voting power.
Stakeholder Impact
- Shareholders: The filing confirms Lilly Endowment, Inc. as a major, stable shareholder with significant voting power, which can influence corporate decisions.
- Eli Lilly and Company: The continued substantial holding by Lilly Endowment, Inc. signals ongoing support and confidence in the company's long-term strategy.
Key Dates
| Date | Description |
|---|---|
| 02/25/2026 | Date of the most recent publicly available information on Eli Lilly and Company's outstanding shares. |
| 03/31/2026 | Date as of which the beneficial ownership is reported. |
| 04/20/2026 | Date of the signature on the Schedule 13G filing. |
Keywords
Eli Lilly and Company, Lilly Endowment, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Shareholder
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.